Cannabinoid type 1 receptor antagonists for smoking cessation.

Journal article

BACKGROUND: Selective type 1 cannabinoid (CB1) receptor antagonists may assist with smoking cessation by restoring the balance of the endocannabinoid system, which can be disrupted by prolonged use of nicotine. They also seeks to address many smokers' reluctance to persist with a quit attempt because of concerns about weight gain. OBJECTIVES: To determine whether selective CB1 receptor antagonists (currently rimonabant and taranabant) increase the numbers of people stopping smoking To assess...

Expand abstract

Authors: Cahill, K; Ussher, M

• Publication status: Published
• Journal: Cochrane database of systematic reviews
• Issue: 3
• Pages: CD005353
• Publication date: 2011-01-01
• DOI: 10.1002/14651858.cd005353.pub4
• EISSN: 1469-493X
• ISSN: 1469-493X
• Language: English
• Keywords: Pyridines; Piperidines; Smoking; Smoking Cessation; Receptor, Cannabinoid, CB1; Body Weight; Amides; Randomized Controlled Trials as Topic; Recurrence; Pyrazoles; Humans